Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment.
• A subset of CML cells, termed minimal residual disease (MRD), is resistant to TKIs.
• The mechanisms underlying TKI resistance in MRD cells remain largely unknown.

Purpose of the Study:

• To investigate the molecular mechanisms driving TKI resistance in CML MRD cells.
• To identify novel therapeutic targets for overcoming TKI resistance in CML.

Main Methods:

• Comparative gene expression analysis using microarrays to identify differentially expressed genes in TKI-sensitive and -resistant CML cells.
• In vitro and in vivo validation of identified target genes (c-Fos and Dusp1) in genetic and humanized mouse models.
• Assessment of therapeutic efficacy of targeting c-Fos and Dusp1 in combination with TKIs.

Main Results:

• Elevated expression of c-Fos and Dusp1 was identified in TKI-resistant CML MRD cells.
• Convergent oncogenic and growth factor signaling pathways contribute to increased c-Fos and Dusp1 expression.
• Genetic or chemical inhibition of c-Fos and Dusp1 restored sensitivity to TKIs and eradicated CML in preclinical models.

Conclusions:

• c-Fos and Dusp1 are key mediators of TKI resistance in CML.
• Targeting c-Fos and Dusp1 represents a promising therapeutic strategy to overcome TKI resistance and achieve CML cure.
• The presented methods facilitate target validation for therapeutic development in CML.